# SEELOS THERAPEUTICS, INC.

SEELOS THERAPEUTICS, INC. is a company headquartered in New York, NY, United States.

## Company overview

- **Legal name:** SEELOS THERAPEUTICS, INC.
- **Former names in filing history:** APRICUS BIOSCIENCES, INC. (2010-09-08 to 2019-01-24); NEXMED INC (1997-06-05 to 2010-09-13)
- **Classification:** Company
- **Industry (SIC):** 2834 — Pharmaceutical Preparations
- **Headquarters:** New York, NY, United States
- **Incorporated in:** NV
- **Fiscal year end:** December 31
- **SEC CIK:** 0001017491

## About

SEELOS THERAPEUTICS, INC. is identified in the retained SEC EDGAR snapshot dated 2026-10-14. Its SEC Central Index Key is 0001017491, and its reported industry is Pharmaceutical Preparations. In 10-K filed on 2024-03-06, it reported annual revenue of USD 2,203,000; net income of USD -37,882,000; total assets of USD 5,418,000 for the fiscal period ended 2023-12-31. The financial history preserves reporting periods, currencies, filing accessions and source provenance. Figures are reported filing data, rather than real-time estimates.

## Financials

Annual figures as originally reported. Currency is shown for each fiscal year; B means billion and M means million.

### FY2023 (period ended 2023-12-31)

- **Revenue:** $2.2M (USD 2,203,000)
- **Net income:** -$37.9M (USD -37,882,000)
- **Total assets:** $5.4M (USD 5,418,000)
- **Operating cash flow:** -$23.9M (USD -23,912,000)

### FY2022 (period ended 2022-12-31)

- **Net income:** -$73.5M (USD -73,534,000)
- **Total assets:** $22.7M (USD 22,746,000)
- **Operating cash flow:** -$61.6M (USD -61,604,000)

### FY2021 (period ended 2021-12-31)

- **Net income:** -$66.0M (USD -66,048,000)
- **Total assets:** $83.5M (USD 83,500,000)
- **Cash and equivalents:** $78.7M (USD 78,734,000)

### FY2020 (period ended 2020-12-31)

- **Revenue:** $0 (USD 0)
- **Net income:** -$19.1M (USD -19,101,000)
- **Total assets:** $17.5M (USD 17,494,000)
- **Cash and equivalents:** $15.7M (USD 15,662,000)

## Recent SEC filings

- Form 8-K — filed 2024-11-22 — period 2024-11-15 — CURRENT REPORT
- Form SC 13G — filed 2024-11-05
- Form 8-K — filed 2024-10-24 — period 2024-10-24 — FORM 8-K
- Form 8-K — filed 2024-10-15 — period 2024-10-14 — FORM 8-K
- Form 8-K — filed 2024-10-07 — period 2024-10-01 — FORM 8-K
- Form 8-K — filed 2024-09-26 — period 2024-09-26 — FORM 8-K
- Form 8-K — filed 2024-09-25 — period 2024-09-25 — FORM 8-K
- Form S-1 — filed 2024-09-25 — FORM S-1
- Form 8-K — filed 2024-09-24 — period 2024-09-24 — FORM 8-K
- Form 8-K — filed 2024-09-03 — period 2024-09-03 — FORM 8-K
- Form DEF 14A — filed 2024-08-20 — period 2024-09-27 — DEF 14A
- Form 10-Q — filed 2024-08-14 — period 2024-06-30 — 10-Q

---

Updated: 2026-10-23T20:08:00Z

Canonical page: https://altss.com/profile/seelos-therapeutics-inc

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology